Medacta Forecast, price target & analysts
Medacta Target price 2026 - Analyst rating & recommendation
Medacta Classifications & Recommendation
Medacta Price Target
| Target Price | CHF183.60 |
| Price | CHF109.00 |
| Potential |
68.44%
register free of charge
|
| Number of Estimates | 6 |
|
6 Analysts have issued a price target Medacta 2027 .
The average Medacta target price is CHF183.60.
This is
68.44%
register free of charge
CHF194.25
78.21%
register free of charge
CHF149.48
37.14%
register free of charge
|
|
| A rating was issued by 10 analysts: 8 Analysts recommend Medacta to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Medacta stock has an average upside potential 2027 of
68.44%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million CHF | 645.85 | 727.08 |
| 15.79% | 12.58% | |
| EBITDA Margin | 19.96% | 28.46% |
| 2.89% | 42.59% | |
| Net Margin | 13.96% | 13.62% |
| 13.11% | 2.43% |
7 Analysts have issued a sales forecast Medacta 2026 . The average Medacta sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Medacta EBITDA forecast 2026. The average Medacta EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Medacta Analysts have issued a net profit forecast 2026. The average Medacta net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 4.51 | 4.98 |
| 30.72% | 10.42% | |
| P/E | 21.91 | |
| EV/Sales | 3.32 |
6 Analysts have issued a Medacta forecast for earnings per share. The average Medacta EPS is
This results in the following potential growth metrics and future valuations:
Current Medacta Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Locked
➜
Locked
|
Locked | Jul 13 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jun 30 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Feb 05 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Feb 04 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jan 26 2026 |
| BERENBERG |
Locked
➜
Locked
|
Locked | Jan 25 2026 |
| STIFEL EUROPE |
Locked
➜
Locked
|
Locked | Jan 20 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jul 13 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jun 30 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Feb 05 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Feb 04 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jan 26 2026 |
|
Locked
BERENBERG:
Locked
➜
Locked
|
Jan 25 2026 |
|
Locked
STIFEL EUROPE:
Locked
➜
Locked
|
Jan 20 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
